A system for the continuous directed evolution of proteases rapidly reveals drug-resistance mutations

Nature Communications

Volumn 5, Issue , 2014, Pages

  Dickinson, Bryan C ^a,c   Packer, Michael S ^a   Badran, Ahmed H ^a   Liu, David R ^a,b  

^a HARVARD UNIVERSITY   (United States)

^b HARVARD UNIVERSITY   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASUNAPREVIR; DANOPREVIR; PROTEASE ACTIVATED RNA POLYMERASE; PROTEINASE; RIFAMPICIN; RNA POLYMERASE; UNCLASSIFIED DRUG; ISOQUINOLINE DERIVATIVE; LACTAM; PEPTIDE HYDROLASE; PROTEINASE INHIBITOR; SULFONAMIDE; VIRAL PROTEIN;

BIOCHEMISTRY; BIOLOGICAL DEVELOPMENT; DRUG DEVELOPMENT; DRUG RESISTANCE; ENZYME ACTIVITY; EVOLUTIONARY BIOLOGY; MUTATION; RNA;

ANTIBIOTIC RESISTANCE; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; DIRECTED MOLECULAR EVOLUTION; DRUG SENSITIVITY; GENE EXPRESSION; GENE MUTATION; GENETIC VARIABILITY; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PHAGE ASSISTED CONTINUOUS EVOLUTION; PHAGE DISPLAY; PROTEIN DEGRADATION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; AMINO ACID SEQUENCE; ANTIVIRAL RESISTANCE; ENTEROBACTERIA PHAGE M13; ENZYMOLOGY; GENETIC PROCEDURES; GENETICS; HEPACIVIRUS; MOLECULAR EVOLUTION; MOLECULAR GENETICS; MUTATION;

HEPATITIS C VIRUS;

AMINO ACID SEQUENCE; BACTERIOPHAGE M13; DRUG RESISTANCE, VIRAL; EVOLUTION, MOLECULAR; GENE EXPRESSION; GENETIC TECHNIQUES; HEPACIVIRUS; HUMANS; ISOQUINOLINES; LACTAMS; MOLECULAR SEQUENCE DATA; MUTATION; PEPTIDE HYDROLASES; PROTEASE INHIBITORS; SULFONAMIDES; VIRAL PROTEINS;

EID: 84923266286     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms6352     Document Type: Article

References (50)

1. Schilling, O. & Overall, C. M. Proteome-derived, database-searchable peptide libraries for identifying protease cleavage sites. Nat. Biotechnol. 26, 685-694 (2008).
2. Walsh, G. Biopharmaceutical benchmarks 2006. Nat. Biotechnol. 24, 769-776 (2006).
3. Wehr, M. C. et al. Monitoring regulated protein-protein interactions using split TEV. Nat. Methods 3, 985-993 (2006).
4. Craik, C. S., Page, M. J. & Madison, E. L. Proteases as therapeutics. Biochem. J. 435, 1-16 (2011).
5. Gray, D. C., Mahrus, S. & Wells, J. A. Activation of specific apoptotic caspases with an engineered small-molecule-activated protease. Cell 142, 637-646 (2010).
6. von Mehren, M., Adams, G. P. & Weiner, L. M. Monoclonal antibody therapy for cancer. Annu. Rev. Med. 54, 343-369 (2003).
7. Waldmann, T. A. Immunotherapy: past, present and future. Nat. Med. 9, 269-277 (2003).
8. Caravella, J. & Lugovskoy, A. Design of next-generation protein therapeutics. Curr. Opin. Chem. Biol. 14, 520-528 (2010).
9. Russell, A. J. & Fersht, A. R. Rational modification of enzyme catalysis by engineering surface charge. Nature 328, 496-500 (1987).
10. Varadarajan, N., Gam, J., Olsen, M. J., Georgiou, G. & Iverson, B. L. Engineering of protease variants exhibiting high catalytic activity and exquisite substrate selectivity. Proc. Natl Acad. Sci. USA 102, 6855-6860 (2005).
11. Knight, Z. A., Garrison, J. L., Chan, K., King, D. S. & Shokat, K. M. A remodelled protease that cleaves phosphotyrosine substrates. J. Am. Chem. Soc. 129, 11672-11673 (2007).
12. Sellamuthu, S. et al. Engineering of protease variants exhibiting altered substrate specificity. Biochem. Biophys. Res. Commun. 371, 122-126 (2008).
13. Varadarajan, N., Rodriguez, S., Hwang, B. Y., Georgiou, G. & Iverson, B. L. Highly active and selective endopeptidases with programmed substrate specificities. Nat. Chem. Biol. 4, 290-294 (2008).
14. Yi, L. et al. Engineering of TEV protease variants by yeast ER sequestration screening (YESS) of combinatorial libraries. Proc. Natl Acad. Sci. USA 110, 7229-7234 (2013).
15. Abbenante, G. & Fairlie, D. P. Protease inhibitors in the clinic. Med. Chem. 1, 71-104 (2005).
16. Turk, B. Targeting proteases: successes, failures and future prospects. Nat. Rev. Drug Discov. 5, 785-799 (2006).
17. Rong, L., Dahari, H., Ribeiro, R. M. & Perelson, A. S. Rapid emergence of protease inhibitor resistance in hepatitis C virus. Sci. Transl. Med. 2, 30ra32 (2010).
18. Ridky, T. & Leis, J. Development of drug resistance to HIV-1 protease inhibitors. J. Biol. Chem. 270, 29621-29623 (1995).
19. Lefebvre, E. & Schiffer, C. A. Resilience to resistance of HIV-1 protease inhibitors: profile of darunavir. AIDS Rev. 10, 131-142 (2008).
20. Romano, K. P. et al. The molecular basis of drug resistance against hepatitis C virus NS3/4A protease inhibitors. PLoS Pathog. 8, e1002832 (2012).
21. Shang, L., Lin, K. & Yin, Z. Resistance mutations against HCV protease inhibitors and antiviral drug design. Curr. Pharm. Des. 20, 694-703 (2014).
22. Verbinnen, T. et al. Tracking the evolution of multiple in vitro hepatitis C virus replicon variants under protease inhibitor selection pressure by 454 deep sequencing. J. Virol. 84, 11124-11133 (2010).
23. Billerbeck, E., de Jong, Y., Dorner, M., de la Fuente, C. & Ploss, A. Animal models for hepatitis C. Curr. Top. Microbiol. Immunol. 369, 49-86 (2013).
24. Orencia, M. C., Yoon, J. S., Ness, J. E., Stemmer, W. P. & Stevens, R. C. Predicting the emergence of antibiotic resistance by directed evolution and structural analysis. Nat. Struct. Biol. 8, 238-242 (2001).
25. Esvelt, K. M., Carlson, J. C. & Liu, D. R. A system for the continuous directed evolution of biomolecules. Nature 472, 499-503 (2011).
26. Hedstrom, L., Szilagyi, L. & Rutter, W. J. Converting trypsin to chymotrypsin: the role of surface loops. Science 255, 1249-1253 (1992).
27. Kim, J. L. et al. Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide. Cell 87, 343-355 (1996).
28. Dickinson, B. C., Leconte, A. M., Allen, B., Esvelt, K. M. & Liu, D. R. Experimental interrogation of the path dependence and stochasticity of protein evolution using phage-assisted continuous evolution. Proc. Natl Acad. Sci. USA 110, 9007-9012 (2013).
29. Leconte, A. M. et al. A population-based experimental model for protein evolution: effects of mutation rate and selection stringency on evolutionary outcomes. Biochemistry 52, 1490-1499 (2013).
30. Carlson, J. C., Badran, A. H., Guggiana-Nilo, D. A. & Liu, D. R. Negative selection and stringency modulation in phage-assisted continuous evolution. Nat. Chem. Biol. 10, 216-222 (2014).
31. Entus, R., Aufderheide, B. & Sauro, H. M. Design and implementation of three incoherent feed-forward motif based biological concentration sensors. Syst. Synth. Biol. 1, 119-128 (2007).
32. Jeruzalmi, D. & Steitz, T. A. Structure of T7 RNA polymerase complexed to the transcriptional inhibitor T7 lysozyme. EMBO J. 17, 4101-4113 (1998).
33. Clark, V. C., Peter, J. A. & Nelson, D. R. New therapeutic strategies in HCV: second-generation protease inhibitors. Liver Int. 33(Suppl 1): 80-84 (2013).
34. Manns, M. P. & von Hahn, T. Novel therapies for hepatitis C - one pill fits all? Nat. Rev. Drug Discov. 12, 595-610 (2013).
35. Jiang, Y. et al. Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease. J. Med. Chem. 57, 1753-1769 (2014).
36. Scola, P. M. et al. The discovery of asunaprevir (BMS-650032), an orally efficacious NS3 protease inhibitor for the treatment of hepatitis C virus infection. J. Med. Chem. 57, 1730-1752 (2014).
37. Lim, S. R. et al. Virologic escape during danoprevir (ITMN-191/RG7227) monotherapy is hepatitis C virus subtype dependent and associated with R155K substitution. Antimicrob. Agents Chemother. 56, 271-279 (2012).
38. McPhee, F. et al. Resistance analysis of the hepatitis C virus NS3 protease inhibitor asunaprevir. Antimicrob. Agents Chemother. 56, 3670-3681 (2012).
39. McPhee, F. et al. Resistance analysis of hepatitis C virus genotype 1 prior treatment null responders receiving daclatasvir and asunaprevir. Hepatology 58, 902-911 (2013).
40. Imhof, I. & Simmonds, P. Genotype differences in susceptibility and resistance development of hepatitis C virus to protease inhibitors telaprevir (VX-950) and danoprevir (ITMN-191). Hepatology 53, 1090-1099 (2011).
41. Kapust, R. B. et al. Tobacco etch virus protease: mechanism of autolysis and rational design of stable mutants with wild-type catalytic proficiency. Protein Eng. 14, 993-1000 (2001).
42. Romano, K. P., Ali, A., Royer, W. E. & Schiffer, C. A. Drug resistance against HCV NS3/4A inhibitors is defined by the balance of substrate recognition versus inhibitor binding. Proc. Natl Acad. Sci. USA 107, 20986-20991 (2010).
43. Herman, G. E. & Modrich, P. Escherichia coli K-12 clones that overproduce dam methylase are hypermutable. J. Bacteriol. 145, 644-646 (1981).
44. Fijalkowska, I. J. & Schaaper, R. M. Mutants in the Exo I motif of Escherichia coli dnaQ: defective proofreading and inviability due to error catastrophe. Proc. Natl Acad. Sci. USA 93, 2856-2861 (1996).
45. Yang, H., Wolff, E., Kim, M., Diep, A. & Miller, J. H. Identification of mutator genes and mutational pathways in Escherichia coli using a multicopy cloning approach. Mol. Microbiol. 53, 283-295 (2004).
46. Bagg, A., Kenyon, C. J. & Walker, G. C. Inducibility of a gene product required for UV and chemical mutagenesis in Escherichia coli. Proc. Natl Acad. Sci. USA 78, 5749-5753 (1981).
47. Burckhardt, S. E., Woodgate, R., Scheuermann, R. H. & Echols, H. UmuD mutagenesis protein of Escherichia coli: overproduction, purification, and cleavage by RecA. Proc. Natl Acad. Sci. USA 85, 1811-1815 (1988).
48. Mahdi, A. A., Buckman, C., Harris, L. & Lloyd, R. G. Rep and PriA helicase activities prevent RecA from provoking unnecessary recombination during replication fork repair. Genes Dev. 20, 2135-2147 (2006).
49. Carlson, J. C., Badran, A. H., Guggiana-Nilo, D. A. & Liu, D. R. Negative selection and stringency modulation enable phage-assisted continuous evolution (PACE) of enzymes with altered specificity. Nat. Chem. Biol. 10, 216-222 Accepted (2013).
50. Cupples, C. G. & Miller, J. H. A set of lacZ mutations in Escherichia coli that allow rapid detection of each of the six base substitutions. Proc. Natl Acad. Sci. USA 86, 5345-5349 (1989).